Cell Therapeutics (CTIC) 2.81 $CTIC
Acquisitions, Study Results, Merger Agreements, and Completed Trial Recruitments - Analyst Notes on Cooper, Agenus, Transcept, CTI and ANI
PR Newswire - Fri Jul 04, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding The Cooper Companies Inc. (NYSE: COO), Agenus Inc. (NASDAQ: AGEN), Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT), Cell Therapeutics, Inc. (NASDAQ: CTIC) and ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4446-100free.
Cell Therapeutics Up 8.5%, Shares Break Through Resistance (CTIC)
Comtex SmarTrend(R) - Tue Jul 01, 10:39AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 8.5% to $3.05 on 1.0x average daily volume. Thus far today, Cell Therapeutics has traded 2.1 million shares, vs. average volume of 2.1 million shares per day. The stock has outperformed the Dow (8.5% to the Dow's 0.8%) and outperformed the S&P 500 (8.5% to the S&P's 0.7%) during today's trading.
Tuesday’s Top Biotech Stories: CTI BioPharma, Agenus, and Salix Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Tue Jul 01, 8:19AM CDT
Let's take a look at three stocks -- CTI BioPharma , Agenus , and Salix Pharmaceuticals -- which are all climbing higher in pre-market trading this Tuesday morning. CTI BioPharma climbs after completing enrollment in a late-stage trial ...
CTI BioPharma Completes Recruitment in PERSIST-1 Pivotal Phase 3 Trial of Pacritinib for Patients with Myelofibrosis
PR Newswire - Tue Jul 01, 12:30AM CDT
CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis. Under the development and commercialization agreement for pacritinib with Baxter International, Inc. (Baxter), CTI expects to receive a $20 million development milestone payment in connection with the first treatment dosing of the last patient enrolled in PERSIST-1. CTI expects to achieve this milestone and receive payment by mid-third quarter 2014.
Insider Trading Alert - FII, RP And CTIC Traded By Insiders
at The Street - Mon Jun 30, 9:30AM CDT
Stocks with insider trader activity include FII, RP and CTIC
Biotech Stocks on the Move -- Research on CTI BioPharma, BioMarin Pharma, Vertex Pharma, and Northwest Biotherapeutics
PR Newswire - Fri Jun 27, 6:00AM CDT
On Thursday, June 26, 2014, the NASDAQ Composite ended at 4,379.05, down 0.02%, the Dow Jones Industrial Average declined 0.13%, to finish the day at 16,846.13, and the S&P 500 closed at 1,957.22, down 0.12%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 708.54, up 0.06%, with the index also advancing 5.43% in the previous three months. Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corp. (NASDAQ: CTIC), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Northwest Biotherapeutics Inc. (NASDAQ: NWBO). Free technical research on CTIC, BMRN, VRTX and NWBO can be downloaded upon signing up at:
Approvals, Agreements, Name Change, and Partnerships - Analyst Notes on Johnson & Johnson, Furiex Pharmaceuticals, Select Medical, CTI and Hill-Rom
PR Newswire - Fri Jun 13, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), Select Medical Holdings Corporation (NYSE: SEM), CTI BioPharma Corp. (NASDAQ: CTIC) and Hill-Rom Holdings, Inc. (NYSE: HRC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3701-100free.
CTI Announces United Kingdom National Cancer Research Institute AML Cooperative Group Initiates Randomized Phase 2 Trial Evaluating Tosedostat plus Cytarabine for Older Patients with AML or High-Risk MDS
PR Newswire - Thu Jun 12, 12:30AM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of tosedostat in combination with low-dose cytarabine in older patients with Acute Myeloid Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival. The trial is being conducted by the National Cancer Research Institute Haematological Oncology Study Group under the sponsorship of Cardiff University. The trial management group is led by Professor Alan K. Burnett, Head of Haematology in the Department of Medical Genetics, Haematology and Pathology at the School of Medicine at Cardiff University. Chroma Therapeutics Ltd., from whom CTI licensed tosedostat, is facilitating drug supply for the trial.
Insider Trading Alert - MWE, CPT And CTIC Traded By Insiders
at The Street - Mon Jun 09, 9:16AM CDT
Stocks with insider trader activity include MWE, CPT and CTIC
Cell Therapeutics reports rebranding of its corporate name
M2 - Fri May 30, 3:06AM CDT
Biopharmaceutical company Cell Therapeutics (NASDAQ:CTIC)(MTA:CTIC) announced on Friday a change in its corporate name to CTI BioPharma with immediate effect.
Cell Therapeutics, Inc. Announces Change of Name to CTI BioPharma Corp.
PR Newswire - Fri May 30, 12:30AM CDT
Cell Therapeutics, Inc. (CTI or the Company) (NASDAQ and MTA: CTIC), a biopharmaceutical company focused on acquiring, developing and bringing to market novel targeted therapies for blood-related cancers, today announced that it will change its corporate name to CTI BioPharma Corp. effective May 30, 2014. The Company's common stock will continue to trade under its current ticker symbol: "CTIC."
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Cell Therapeutics, Inc. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Thu May 29, 11:52AM CDT
Levi & Korsinsky, LLP is investigating Cell Therapeutics, Inc. (NasdaqCM: CTIC) in connection with possible claims of breaches of fiduciary duty by certain members of the board of directors of the Company.
CollabRx's Mobile App Simplifies Cancer Treatment Options
ACCESSWIRE - Thu May 29, 9:46AM CDT
WHITEFISH, MT / May 29, 2014 / Treating cancer patients has become increasingly difficult given the condition's incredibly wide scope. For example, breast cancer can be treated in two very different ways depending on whether a patient is HER2 positive, triple negative, triple positive, or endocrine receptor positive. These types of tests and treatments are only increasing in scope as more genetic markers are discovered.
Cell Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire - Thu May 29, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4 at 11:30 a.m. PDT/2:30 p.m. EDT/8:30 p.m. CEST in New York.
Top Gainers on the Move -- Research on Aeropostale, FirstEnergy, Cell Therapeutics, and Dyax
PR Newswire - Wed May 28, 4:00AM CDT
The US markets saw a positive sentiment on Tuesday, May 27, 2014, with the NASDAQ Composite closing at 4,237.07, up 1.22%, the Dow Jones Industrial Average ending the session at 16,675.50, up 0.42% and the S&P 500 edging 0.60% higher to finish the trading session at 1,911.91. The gains were broad based as nine out of ten sectors ended the session in positive. A number of stocks saw large movements, including Aeropostale Inc. (NYSE: ARO), FirstEnergy Corp. (NYSE: FE), Cell Therapeutics Inc. (NASDAQ: CTIC) and Dyax Corp. (NASDAQ: DYAX). Free technical research on ARO, FE, CTIC and DYAX can be downloaded upon signing up at:
Stock to Watch: Cell Therapeutics Up 7.0% (CTIC)
Comtex SmarTrend(R) - Tue May 27, 11:41AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 7.0% to $3.06 on 1.0x average daily volume. Cell Therapeutics has traded 2.6 million shares thus far today, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (7.0% to the Dow's 0.3%) and outperformed the S&P 500 (7.0% to the S&P's 0.4%) during today's trading.
Why NTELOS, Cell Therapeutics, and Sanchez Energy Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu May 22, 4:28PM CDT
When things are going right, not even mixed economic data can push the broad-based S&P 500 lower. The headline story that I would have expected to pressure the S&P 500 throughout the day was the weekly initial jobless claims figure....
Why Cell Therapeutics (CTIC) Stock Is Spiking Today
at The Street - Thu May 22, 11:27AM CDT
Cell Therapeutics (CTIC) is rocketing up today after being initiated with a 'buy' rating by analysts at Ladenburg (LTS).
Stock to Watch: Cell Therapeutics Up 12.2% (CTIC)
Comtex SmarTrend(R) - Thu May 22, 10:10AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 12.2% to $2.85 on 1.0x average daily volume. Cell Therapeutics has traded 2.6 million shares thus far today, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (12.2% to the Dow's 0.2%) and outperformed the S&P 500 (12.2% to the S&P's 0.3%) during today's trading.
Acquisitions, Study Results, Merger Agreements, and Completed Trial Recruitments - Analyst Notes on Cooper, Agenus, Transcept, CTI and ANI
PR Newswire - Fri Jul 04, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding The Cooper Companies Inc. (NYSE: COO), Agenus Inc. (NASDAQ: AGEN), Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT), Cell Therapeutics, Inc. (NASDAQ: CTIC) and ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4446-100free.
Cell Therapeutics Up 8.5%, Shares Break Through Resistance (CTIC)
Comtex SmarTrend(R) - Tue Jul 01, 10:39AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 8.5% to $3.05 on 1.0x average daily volume. Thus far today, Cell Therapeutics has traded 2.1 million shares, vs. average volume of 2.1 million shares per day. The stock has outperformed the Dow (8.5% to the Dow's 0.8%) and outperformed the S&P 500 (8.5% to the S&P's 0.7%) during today's trading.
Tuesday’s Top Biotech Stories: CTI BioPharma, Agenus, and Salix Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Tue Jul 01, 8:19AM CDT
Let's take a look at three stocks -- CTI BioPharma , Agenus , and Salix Pharmaceuticals -- which are all climbing higher in pre-market trading this Tuesday morning. CTI BioPharma climbs after completing enrollment in a late-stage trial ...
CTI BioPharma Completes Recruitment in PERSIST-1 Pivotal Phase 3 Trial of Pacritinib for Patients with Myelofibrosis
PR Newswire - Tue Jul 01, 12:30AM CDT
CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis. Under the development and commercialization agreement for pacritinib with Baxter International, Inc. (Baxter), CTI expects to receive a $20 million development milestone payment in connection with the first treatment dosing of the last patient enrolled in PERSIST-1. CTI expects to achieve this milestone and receive payment by mid-third quarter 2014.
Insider Trading Alert - FII, RP And CTIC Traded By Insiders
at The Street - Mon Jun 30, 9:30AM CDT
Stocks with insider trader activity include FII, RP and CTIC
Biotech Stocks on the Move -- Research on CTI BioPharma, BioMarin Pharma, Vertex Pharma, and Northwest Biotherapeutics
PR Newswire - Fri Jun 27, 6:00AM CDT
On Thursday, June 26, 2014, the NASDAQ Composite ended at 4,379.05, down 0.02%, the Dow Jones Industrial Average declined 0.13%, to finish the day at 16,846.13, and the S&P 500 closed at 1,957.22, down 0.12%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 708.54, up 0.06%, with the index also advancing 5.43% in the previous three months. Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corp. (NASDAQ: CTIC), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Northwest Biotherapeutics Inc. (NASDAQ: NWBO). Free technical research on CTIC, BMRN, VRTX and NWBO can be downloaded upon signing up at:
Approvals, Agreements, Name Change, and Partnerships - Analyst Notes on Johnson & Johnson, Furiex Pharmaceuticals, Select Medical, CTI and Hill-Rom
PR Newswire - Fri Jun 13, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), Select Medical Holdings Corporation (NYSE: SEM), CTI BioPharma Corp. (NASDAQ: CTIC) and Hill-Rom Holdings, Inc. (NYSE: HRC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3701-100free.
CTI Announces United Kingdom National Cancer Research Institute AML Cooperative Group Initiates Randomized Phase 2 Trial Evaluating Tosedostat plus Cytarabine for Older Patients with AML or High-Risk MDS
PR Newswire - Thu Jun 12, 12:30AM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of tosedostat in combination with low-dose cytarabine in older patients with Acute Myeloid Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival. The trial is being conducted by the National Cancer Research Institute Haematological Oncology Study Group under the sponsorship of Cardiff University. The trial management group is led by Professor Alan K. Burnett, Head of Haematology in the Department of Medical Genetics, Haematology and Pathology at the School of Medicine at Cardiff University. Chroma Therapeutics Ltd., from whom CTI licensed tosedostat, is facilitating drug supply for the trial.
Insider Trading Alert - MWE, CPT And CTIC Traded By Insiders
at The Street - Mon Jun 09, 9:16AM CDT
Stocks with insider trader activity include MWE, CPT and CTIC
Cell Therapeutics reports rebranding of its corporate name
M2 - Fri May 30, 3:06AM CDT
Biopharmaceutical company Cell Therapeutics (NASDAQ:CTIC)(MTA:CTIC) announced on Friday a change in its corporate name to CTI BioPharma with immediate effect.
Cell Therapeutics, Inc. Announces Change of Name to CTI BioPharma Corp.
PR Newswire - Fri May 30, 12:30AM CDT
Cell Therapeutics, Inc. (CTI or the Company) (NASDAQ and MTA: CTIC), a biopharmaceutical company focused on acquiring, developing and bringing to market novel targeted therapies for blood-related cancers, today announced that it will change its corporate name to CTI BioPharma Corp. effective May 30, 2014. The Company's common stock will continue to trade under its current ticker symbol: "CTIC."
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Cell Therapeutics, Inc. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Thu May 29, 11:52AM CDT
Levi & Korsinsky, LLP is investigating Cell Therapeutics, Inc. (NasdaqCM: CTIC) in connection with possible claims of breaches of fiduciary duty by certain members of the board of directors of the Company.
CollabRx's Mobile App Simplifies Cancer Treatment Options
ACCESSWIRE - Thu May 29, 9:46AM CDT
WHITEFISH, MT / May 29, 2014 / Treating cancer patients has become increasingly difficult given the condition's incredibly wide scope. For example, breast cancer can be treated in two very different ways depending on whether a patient is HER2 positive, triple negative, triple positive, or endocrine receptor positive. These types of tests and treatments are only increasing in scope as more genetic markers are discovered.
Cell Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire - Thu May 29, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4 at 11:30 a.m. PDT/2:30 p.m. EDT/8:30 p.m. CEST in New York.
Top Gainers on the Move -- Research on Aeropostale, FirstEnergy, Cell Therapeutics, and Dyax
PR Newswire - Wed May 28, 4:00AM CDT
The US markets saw a positive sentiment on Tuesday, May 27, 2014, with the NASDAQ Composite closing at 4,237.07, up 1.22%, the Dow Jones Industrial Average ending the session at 16,675.50, up 0.42% and the S&P 500 edging 0.60% higher to finish the trading session at 1,911.91. The gains were broad based as nine out of ten sectors ended the session in positive. A number of stocks saw large movements, including Aeropostale Inc. (NYSE: ARO), FirstEnergy Corp. (NYSE: FE), Cell Therapeutics Inc. (NASDAQ: CTIC) and Dyax Corp. (NASDAQ: DYAX). Free technical research on ARO, FE, CTIC and DYAX can be downloaded upon signing up at:
Stock to Watch: Cell Therapeutics Up 7.0% (CTIC)
Comtex SmarTrend(R) - Tue May 27, 11:41AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 7.0% to $3.06 on 1.0x average daily volume. Cell Therapeutics has traded 2.6 million shares thus far today, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (7.0% to the Dow's 0.3%) and outperformed the S&P 500 (7.0% to the S&P's 0.4%) during today's trading.
Why NTELOS, Cell Therapeutics, and Sanchez Energy Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu May 22, 4:28PM CDT
When things are going right, not even mixed economic data can push the broad-based S&P 500 lower. The headline story that I would have expected to pressure the S&P 500 throughout the day was the weekly initial jobless claims figure....
Why Cell Therapeutics (CTIC) Stock Is Spiking Today
at The Street - Thu May 22, 11:27AM CDT
Cell Therapeutics (CTIC) is rocketing up today after being initiated with a 'buy' rating by analysts at Ladenburg (LTS).
Stock to Watch: Cell Therapeutics Up 12.2% (CTIC)
Comtex SmarTrend(R) - Thu May 22, 10:10AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 12.2% to $2.85 on 1.0x average daily volume. Cell Therapeutics has traded 2.6 million shares thus far today, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (12.2% to the Dow's 0.2%) and outperformed the S&P 500 (12.2% to the S&P's 0.3%) during today's trading.
